498 related articles for article (PubMed ID: 28875855)
1. Impurity Profile of Bronchodilators used in Asthma: A Critical Review.
Prajapati KJ; Kothari CS
Curr Drug Discov Technol; 2018; 15(4):272-304. PubMed ID: 28875855
[TBL] [Abstract][Full Text] [Related]
2. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
3. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.
Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL
J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687
[TBL] [Abstract][Full Text] [Related]
4. Development of Impurity Profiling Methods Using Modern Analytical Techniques.
Ramachandra B
Crit Rev Anal Chem; 2017 Jan; 47(1):24-36. PubMed ID: 27070830
[TBL] [Abstract][Full Text] [Related]
5. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products.
Singh S; Handa T; Narayanam M; Sahu A; Junwal M; Shah RP
J Pharm Biomed Anal; 2012 Oct; 69():148-73. PubMed ID: 22521633
[TBL] [Abstract][Full Text] [Related]
6. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
[TBL] [Abstract][Full Text] [Related]
7. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
[TBL] [Abstract][Full Text] [Related]
8. Comparison between liquid chromatography-UV detection and liquid chromatography-mass spectrometry for the characterization of impurities and/or degradants present in trimethoprim tablets.
Barbarin N; Henion JD; Wu Y
J Chromatogr A; 2002 Sep; 970(1-2):141-54. PubMed ID: 12350089
[TBL] [Abstract][Full Text] [Related]
9. Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.
Chen Q; Zielinski D; Chen J; Nowak S; Zhou CC
J Pharm Biomed Anal; 2009 Dec; 50(5):778-86. PubMed ID: 19581067
[TBL] [Abstract][Full Text] [Related]
10. Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development.
Stolarczyk EU; Rosa A; Kubiszewski M; Zagrodzka J; Cybulski M; Kaczmarek Ł
Eur J Pharm Sci; 2017 Nov; 109():389-401. PubMed ID: 28865686
[TBL] [Abstract][Full Text] [Related]
11. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
12. Identification of pharmaceutical impurities in formulated dosage forms.
Pan C; Liu F; Motto M
J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
[TBL] [Abstract][Full Text] [Related]
13. Potential impurities of anxiolytic drug, clobazam: Identification, synthesis and characterization using HPLC, LC-ESI/MS
Kumar N; Devineni SR; Dubey SK; Kumar P
J Pharm Biomed Anal; 2017 Apr; 137():268-278. PubMed ID: 28183048
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
[TBL] [Abstract][Full Text] [Related]
15. Drug impurity profiling strategies.
Görög S; Babják M; Balogh G; Brlik J; Csehi A; Dravecz F; Gasdag M; Horváth P; Laukó A; Varga K
Talanta; 1997 Sep; 44(9):1517-26. PubMed ID: 18966892
[TBL] [Abstract][Full Text] [Related]
16. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
[TBL] [Abstract][Full Text] [Related]
17. [Estimation of impurity profiles of drugs and related materials. 20. Methodological problems in the identification and determination of organic impurities].
Görög S
Acta Pharm Hung; 2000; 70(3-6):131-7. PubMed ID: 11379019
[TBL] [Abstract][Full Text] [Related]
18. Stability-indicating HPLC method development and structural elucidation of novel degradation products in posaconazole injection by LC-TOF/MS, LC-MS/MS and NMR.
Yang Y; Zhu X; Zhang F; Li W; Wu Y; Ding L
J Pharm Biomed Anal; 2016 Jun; 125():165-77. PubMed ID: 27023129
[TBL] [Abstract][Full Text] [Related]
19. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
[TBL] [Abstract][Full Text] [Related]
20. Characterization of two unknown impurities in roxithromycin by 2D LC-QTOF/MS/MS and NMR.
Wang J; Zhou J; Xu Y; Zhu B; Jin Y
J Pharm Biomed Anal; 2020 May; 184():113196. PubMed ID: 32113121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
